乐普基因
乐普基因在保持全资子公司北京爱普益医学检验中心现有的生化、免疫、微生物、血液病、遗传代谢和细胞组织病理的优势前提下,借助二代基因测序平台重点发展心血管高通量基因测序、无创产前筛查基因检测(NIPT)和肿瘤基因测序服务,同时联合北京乐普医疗科技有限责任公司荧光定量PCR技术优势积极开展心血管个体化用药相关的分子诊断试剂的研发、和销售,从而构建一个以分子诊断和高通量测序为基础的涵盖研发、销售和第三方医学检验服务的闭环系统。
在心血管基因和肿瘤测序方面,公司与美国休斯敦医学中心合作开展心血管疾病易感基因检测,涵盖心肌病、遗传性心律失●!⒅鞫霾 ⑾忍煨孕脑嗖 ⒓易逍愿叩ü檀佳ⅰ⒔峁剐孕脑嗉膊〉刃难芗膊。煌笨怪琢鲆赘谢蚣觳饧坝靡┲傅肌⑿律糯患膊』颉⑷橄侔⑻悄虿〉纫赘谢虻募觳庀钅浚辉诜肿诱锒鲜约裂蟹⑾鄯矫妫肜制找搅迫首庸颈本├制找搅瓶萍加邢拊鹑喂疽丫峡⒘诵难芨鎏寤靡┓肿诱锒鲜约粒–YP2C19、CYP2C9、VKORC1、ALDH2),由乐普基因独家销售。
爱普益医学检验中心
北京爱普益医学检验中心是北京市卫生局批准成立的省级医学独立实验室,创立于2007年,是一家专业从事医学检验、医学病理及科研服务等以第三方健康检验为主的科技服务型企业。
美国Quanterix
We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. Click on one of the therapeutic category icons below to learn how our revolutionary technology is helping researchers advance the science of precision health.
Kevin joined Quanterix in 2014 and serves as the Chief Executive Officer and Executive Chairman. While at Quanterix, Kevin has led the Company to achieve significant success and growth, recently securing a $46 million capital raise that elevated the Company’s valuation to ten times its revenue. With over 25 years of experience in the life sciences space, he has dedicated his career to transforming healthcare into personalized medicine, and has a proven track record of